Chronic Inflammatory Demyelinating Polyradiculoneuropathy

DBCOND0030996Immune System Diseases Nervous System Diseases

Chronic Inflammatory Demyelinating Polyradiculoneuropathy is the indication for 3 drugs in DrugBank. It is covered by 5 curated, structured indications.

Also known as: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Chronic Inflammatory Demyelinating Polyneuropathy · CIDP · Polyneuropathy, Inflammatory Demyelinating, Chronic · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Classified under: Immune System Diseases
Nervous System Diseases
Signs and Symptoms
Spinal cord and nerve root disorders
Indicated drugs: Efgartigimod alfa
Human immunoglobulin G
Hyaluronidase (human recombinant)

Resolves to

Vocabularies

MeSHM0328266ICD-10G61.81SNOMED CT128209004MedDRA10057645UMLSC0393819

What you can answer from here — as of September 30, 2026

3Indicated drugsWith each drug's targets and mechanism

Listed above

5Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

89Clinical trialsPhase, status and sponsor resolved per trial

2Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account